ProQR Therapeutics (PRQR) Notes Payables (2017 - 2021)

ProQR Therapeutics' Notes Payables history runs 4 years deep, the most recent figure standing at $5.5 million for Q4 2021.

• In Q4 2021, Notes Payables rose 303.32% year-over-year to $5.5 million; the TTM figure through Dec 2021 stood at $5.5 million (up 303.32% YoY), while the FY2021 annual figure was $5.6 million, up 335.68% from the prior year.
• Notes Payables came in at $5.5 million for Q4 2021 at ProQR Therapeutics, down from $21.5 billion in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $21.5 billion in Q1 2021 to a low of $379662.5 in Q4 2019.
• A 4-year average of $4.3 billion and a median of $2.3 million in 2017 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables surged 256.43% in 2020 and surged 303.32% in 2021, its largest moves.
• ProQR Therapeutics' Notes Payables stood at $2.3 million in 2017, then slumped by 83.55% to $379662.5 in 2019, then soared by 256.43% to $1.4 million in 2020, then soared by 303.32% to $5.5 million in 2021.
• According to Business Quant data, Notes Payables over the past three periods registered $5.5 million, $21.5 billion, and $1.4 million for Q4 2021, Q1 2021, and Q4 2020 respectively.

Peer Comparison